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Liquid biopsies to occult brain metastasis
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Surinder K. Batra1,2,4 and Mohd Wasim Nasser1,2*

Abstract
Brain metastasis (BrM) is a major problem associated with cancer-related mortality, and currently, no specific biomarkers are available in clinical settings for early detection. Liquid biopsy is widely accepted as a non-invasive method
for diagnosing cancer and other diseases. We have reviewed the evidence that shows how the molecular alterations
are involved in BrM, majorly from breast cancer (BC), lung cancer (LC), and melanoma, with an inception in how they
can be employed for biomarker development. We discussed genetic and epigenetic changes that influence cancer
cells to breach the blood-brain barrier (BBB) and help to establish metastatic lesions in the uniquely distinct brain
microenvironment. Keeping abreast with the recent breakthroughs in the context of various biomolecules detections
and identifications, the circulating tumor cells (CTC), cell-free nucleotides, non-coding RNAs, secretory proteins, and
metabolites can be pursued in human body fluids such as blood, serum, cerebrospinal fluid (CSF), and urine to obtain
potential candidates for biomarker development. The liquid biopsy-based biomarkers can overlay with current imaging techniques to amplify the signal viable for improving the early detection and treatments of occult BrM.
Keywords: CTCs, Cell-free DNA, microRNA, Brain microenvironment, Cancer diagnostics, Exosomes
Introduction
Tissue biopsy is considered one of the best methods for
accurate cyto−/histologic diagnosis, disease grading,
and revealing novel targets for personalized cancer treatments [1, 2]. However, as our understanding of cancer
over the last decade has unfurled, interpretation of tissue
biopsies have proved to be increasingly challenging, not
just confined to tissue acquisition, which is more salient
when tumors are not accessible, but the major obstacle
is the cancer evolution that further adds to tumor heterogeneity, which is why tissue specimen excised never
portray a complete picture [3–7]. Interestingly, Kwak
et al. reported that treatment on esophagogastric cancer
patients did not work as patients acquired resistance, and
the de novo mechanism of resistance identified KRAS
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mutation that was initially not detected in the excised
tumor tissues. However, the mutant gene responsible for
the resistance was present in the circulating tumor DNA
(ctDNA) isolated from the peripheral blood samples [7].
Therefore, it looks plausible to infer tumor biomarkers
in the systemic circulation and other liquid biopsies that
refer to circulating biomarkers in the form of DNA, RNA,
proteins, and metabolites derived from tumors that can
give a glimpse into cancer features [8–10]. If the diagnosis of neoplastic growth can be made upfront, the chance
of mortality can go down; indeed, disease-free survival is
possible in some cancer types, if not all [11].
The concept of liquid biopsy is based on tumor turnover; as the tumor grows, it releases cancerous cells into
the blood circulation that can seed metastases. These
cells or their biomolecules in the circulation, if detected/
quantified, can lead to diagnosis [12, 13]. The specific
and sensitive identification can reveal the type and anatomical location of the tumors. The FDA has approved
diagnostic kits that utilize CTCs, and ctDNAs in patients
where tissue biopsy excision is clinically not possible,
like Guardant360 (https://www.accessdata.fda.gov/cdrh_
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docs/pdf20/P200010A.pdf ) and Foundation One Liquid CDx (http://www.accessdata.fda. gov/cdrh_docs/
pdf19/P190032A.pdf ). Although RNA is not considered
as a viable analyte due to its unimpressive stability in
the blood, but microRNAs (miRNAs), long non-coding
RNAs (lncRNA), and circular RNAs (cirRNA) in circulation have shown promise in the context of liquid
biopsies [14]. Lately, nanotechnology has also contributed to tumor diagnosis as it can also exploits the tumor
exosomes, supposedly enriched in DNA, RNA, and proteins [15]. Moreover, with the advent of more sophisticated mass spectrometry, tracking the altered cancer
metabolism that is usually cell-specific, has given rise to
neo-metabolite, that can be utilized for designing diagnostic and therapeutic strategies [16].
Lung, liver, brain, and bone are the major metastatic
sites and encompass specific characteristics leading
to organ-specific tropism of cancer cells [17]. As in the
case of BC, relapse occurs even after years of primary
tumor removal, suggesting that these cells could have
acquired specialized features to gain access to specific
organs [18]. BrM is the most lethal and unique among
various metastases. It requires cells that can breach the
BBB, an anatomical challenge that also threatens the
success of systemic therapies for brain cancer and other
intracranial diseases. In BrM, it was surprising that the
mutations that were commonly associated among multiple metastatic samples were often absent in the primary tumors from where BrM originated [19, 20]. Most
of our knowledge is derived from in-vitro studies where
enriched cells were obtained by the trans-well endothelial assay or in-vivo by injecting them through intra-cardiac/−carotid routes and isolating these cells from the
brain. These enriched cells, thereby, show the capability to seed, colonize, and subsequently grow in distinct
brain microenvironment [21–25]. Our group has shown
a model where orthotopically transplanted BC cells to
mammary fat pad led to induction of primary breast
tumor that also metastasized to the brain [26]. This way,
various hypotheses can be tested with a rationale to fetch
out molecules and the pathways driven by these effector
molecules that can be causal factors for BrM. Taking cues
from artificial intelligence (AI), an Organ-On-a Chip 3D
model was conceived, where tumor cells traversing the
BBB can be studied. This can help design and interpret
studies to understand the intrinsic phenotypic variations
that could be a potential tool in BrM [27].
The compelling evidence that the ctDNA showed similar mutations present in lung cancer (LC) tissue samples led the FDA to approve the EGFR mutation-based
liquid biopsy test to predict if tyrosine kinase inhibitor
therapy would be responsive [28]. Similarly, immune
cells infiltration in the brain microenvironment and their
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characterization through a non-invasive method like
CSF analysis can help determine the response to various
therapeutic interjections like the feasibility of immune
checkpoint inhibitors (ICI) in BrM patients [29, 30]. Presumptively, the outcomes of blood-based biomarkers can
be enhanced with available screening methods for multiple cancer lesions in various organs. The outcome has
come out to be exciting in some studies, so much that
only 1% showed false-positive blood tests [31].
The recent advances in understanding and non-invasiveness of liquid biopsies put forward its relevance
in cancer diagnosis. Researchers or clinicians have
employed its uses not only in clinical settings but also
in deciphering the mechanism associated with metastasis [32]. Therefore, it is important to discuss our current
understanding of the plethora of diagnoses dependent on
liquid biopsies and major advances made in the realms of
BrM research during the last decade. In this review, we
acknowledge the potential biomarkers associated with
metastasis, specifically those that form secondary tumors
in the central nervous system (CNS). We have discussed
CTCs, ctDNA, micro-RNAs, circular RNAs, lipids, proteins, metabolites, and exosomes that can be detected in
body fluids (Table 1). The compiled information in this
review can help to narrow down on potential biomarkers
for early diagnosis, prognosis and tracking the treatment
response in BrM patients.

Circulating tumor cells

Circulating tumors cells (CTCs) or disseminated cancer
cells are continuously shed from the tumor, survive in the
bloodstream and have shown potential for seeding secondary tumors at new metastatic locations [66]. CTCs
can house at metastatic sites and go dormant, which can
eventually come out of dormancy triggered by various
mechanisms that are still poorly understood [67]. It has
been postulated that the CTCs usually arise early during the primary tumor formation, as mutations found in
metastatic lesions are usually different compared to the
primary lesion, and then both primary and metastatic
lesions evolve separately [68–71]. The kinetics of CTCs
is different in various cancers, may be poised by their
propensity to metastasize, that is usually several thousand of cells shed from a gram of tissue in the circulation, and this can go higher up to 700,000 cells per day
as in the case of small cell lung cancer (SCLC). The halflife of CTCs in circulation is around several minutes [12].
Therefore, thousands of these CTCs remain in circulation
and can seed metastasis in a spatially differentiated manner. Thus, it looks promising to target CTCs that have the
propensity to drive towards a particular organ and characterize these cells.
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Table 1 Liquid biopsies based molecular determinants of BrM in various cancers
S. No. Sample

Cancer Type

Molecular Determinants

Readout

Reference

1

CTCs/Blood/ (N = 10)

BC

EpCAM (+ve) /Notch Signaling

Upregulation in Notch Signaling

[33]

2

CTCs/ctDNA/ Blood/(N = 10) LC

NRF2

Mutations in NRF2 (R34G)

[34]

3

CTCs/Blood/(N = 4)

BC

Semaphorin 4D/GPX1/MYC

High expression of SEMA4D, GPX1
and MYC gene amplification

[35]

4

CTCs/Blood/(N = 38)

BC

HER2+/EGFR+/HPSE+/NOTCH1+

Brain metastasis selected markers

[36]

5

CTCs/Pleural effusion/(N = 3) BC

ST6GALNAC5

The high expression of ST6GALNAC5 facilitates co-option and
passage through BBB

[37, 38]

6

CTCs/CSF/(N = 13)

BC

Syndecan-1 and MUC-1

Overexpression of syndecan-1
and MUC-1 in Leptomeningeal
metastasis

[39]

7

ctDNA/Serum/(N = 311)

NSCLC

EGFR

BrM associated with the EGFR muta- [40]
tion and in concordance with EGFR
status in tissues

8

ctDNA/Blood/(N = 28)

Metastatic Brain tumor ALK, MDM2

BrM associated with the ALK and
MDM2 mutation

[41]

9

ctDNA/Blood/(N = 70)

BC

miR124-2; miR3193; CCDC8

BrM associated with miR124-2,
CCDC8 hypermethylation, and
miR3193 hypomethylation

[42]

10

ctDNA/Blood/(N = 205)

LC

TGF-ß1

rs1982073 mutant

[43]

11

ctDNA/CSF/(N = 21;12)

LC

EGFR

> 50% patients have EGFR mutations

[44, 45]

12

ctDNA/Blood/(N = 92)

Melanoma

BRAF/NRAS

BRAF (V600E/K/D); NRAS (Q61R/L)

[46]

13

Protein/Serum/(N = 379)

LC

Cathepsin F/ Fibulin-1

Cathepsin upregulates in LC
patients’ serum

[47]

14

Protein/Serum/(N = 29)

Brain Metastatic

C-Reactive Protein

C-reactive protein was upregulated
in brain metastatic patients’ blood
as compared to glioblastoma

[48]

15

Protein/Serum/(N = 120)

LC

IL6

Elevated IL6 in serum associated
with BrM

[49]

16

Protein/Serum/(N = 30)

LC

S100ß

Serum has significantly high S100ß

[50]

17

Protein/Serum/(N = 68)

LC

Myelin

Myelin is high in serum

[51]

18

Protein/CSF/(N = 45)

Leukemia

sVEGFR-1,2

Elevated serum levels of sVEGFR-2

[52]

19

Protein/Serum/(N = 147)

BC

Glial fibrillary acidic protein

Elevated serum levels of GFAP

[53]

20

Protein/Serum/(N = 244)

BC

Tau

Elevated serum levels of Tau

[54]

21

Protein/Serum/(N = 68)

LC

Neurofilament Light Chain

Elevated serum levels of NFL

[55]

22

Protein/Serum/(N = 103)

BC

CXCL13; CX3CL1

CXCL13 and CX3CL1 enhances
BBB permeability

[56]

23

Exosome/(N = 75)

LC

Integrinβ3

BrM occurs in patients with high EV
ITGβ3 levels

[57]

24

Exosome/(N = 104)

BC

CEMIP

Tumor derived exosomes enriched
in CEMIP protein promoted BrM

[58]

25

Exosome/(N = 6)

LC

miR-550a35p

miR-550a-3-5p controls the BrM

[59]

26

Exosome/(N = 38)

BC

miR-105

Cancer secreted miR-105 destroys
BBB

[60]

27

Exosome/(N = 65)

LC

miR-335-5p/miR-34b-3p

miR-335-5p & miR-34b-3p
are unique in BrM

[61]

28

Exosome/(N = 56)

BC

miR-181c/miR-503/miR-105

Enriches exosomes promotes BrM

[62, 63]

29

Serum/CSF/(N = 118)

BC

miR-200a, miR-200b, miR-200c,
miR-141

Upregulated in BrM

[64]

30

Serum/(N = 24)

SCLC

LncRNA XR_429159.1

Downregulated in BrM

[65]
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In addition to being a tool for diagnosis and prognosis, CTCs can be instrumental in determining the
molecular landscape of cancer where tumor acquisition
is not clinically possible [72]. Studies revealed how BCs
with a particular transcriptomic profile were often seen
to metastasize to the brain. In those patients, Notch
signaling and genes that control immune evasion like
CXCL8, CXCR4, and CD86 were upregulated [33]. In
another study, SCLC patients were stratified into chemosensitive/refractory based on copy number variation (CNV) in the CTCs isolated from blood [73]. Now,
an early diagnosis can be envisioned if CTCs, isolated
from a patient’s blood or other body fluids, could be
questioned for BrM based on their genetic profile. In
BrM, besides blood or any other body fluids, CSF can
be an ideal matrix as it has exclusive CTCs not available
in the systemic circulation or in the extracranial region
[74, 75].
In the quest to figure out what pattern is observed in
CTCs metastasizing to the brain, the CTCs derived
from patients were injected into mice, and the metastasis was studied. This revealed intrinsic properties of
CTCs like the new role of SEMA4D in cooperation with
MYC and GPX1 as a mediator of extravasation and subsequent BBB transmigration [35]. Similarly, Cathepsin S
(CTSS) is implicated in proteolytically cleaving JAM-B’s
junctional adhesion molecules. Studies have indicated
elevated CTSS in primary tumors and the macrophages
of the stroma in the brain metastatic tumor microenvironment (TME). On depletion in both tissue and stroma,
inhibited metastasis (Fig. 1). However, no significant
changes in tumorigenesis were reported [76, 77]. Cathepsin expression in serum, as seen in NSCLC and the
microenvironment through the CSF, could help assess its
role in non-invasive imaging and diagnosis [78, 79]. Lung
cancer-derived BrM led to the release of CTCs in blood
with mutations in KEAP1-NRF2-ARE pathway genes
[34]. The cytoprotective role of the genes in response to
stress points to their pro-survival in circulation, which
otherwise is highly inefficient. The study suggests that the
mutations in the Keap1-Nrf2-ARE pathway led to higher
expression of antioxidant and detoxification enzymes that
eventually could help cells survive in blood circulation
and metastasize to other distant organs. We have further discussed the mutation in the ctDNA section. It was
also revealed that CTCs have tropism, and only certain
CTCs exclusively metastasized either to the brain, bone,
or liver. Now, this is interesting as not only diagnosis is
possible, but therapeutics can be tailormade by exploiting the disruption of the interaction between SEMA4D
and Plexin-B1 and targeting CTSS, which can eventually
be designed to stop cells from breaching the BBB (43,44).
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In a BC study, patients with BrM had certain CTCs that
were EpCAM negative; however, the same CTCs were
EGFR, NOTCH1, and HPSE-positive [36]. This study was
unique as it target EpCAM negative cells that cannot be
captured through the FDA cleared CTC testing kit CellSearch® platform as it targets only the EpCAM positive
cells, thereby increasing the range for CTCs implicated
in BrM. Cancer cells devoid of the signature were nonmetastatic, showing the critical importance of HPSE
in metastasis [36]. In BC, HER2+ cells are the major
cell types that metastasize to the brain specifically; it is
interesting to note that in triple-negative breast cancer
(TNBC) that metastasize to the brain also has HER2+
CTCs in the blood [80–83]. HER2+ belongs to the EGFR
group of transmembrane receptors involved in tyrosine
signaling and acts as a proto-oncogene. It is still being
investigated the plausible explanation for BrM in such
subtypes [84].
Slow cycle cancer-initiating cells, in blood circulation
were found to be enriched for the stemness features, and
most of them are EpCAM positive along with CD44 and
CD24, and these are competent enough to seed secondary metastasis [85–87]. Stemness markers Oct4/Sox2,
NOTCH, and WNT positive cells were enriched in the
slow cycle subpopulation that eventually developed BrM.
The association of the stem cell markers with BrM was
significant as less than 1% of total cancer cells expressed
these markers and were designated as the slow cycle cells
[87]. The CSCs have been hypothesized to metastasize,
and the existence of stemness marker-specific positive
cells in the circulation could be utilized for diagnosing a
probable BrM [88, 89].
Epithelial-mesenchymal transition (EMT) is induced
by TWIST1 upregulation in LC and BC BrM samples.
In these samples, lower E-Cadherin (involved in cellcell adhesion) expression was observed, showcasing that
TWIST1 could affect E-Cadherin downregulation [90].
Other EMT genes like SOX2, EGFR, and c-MET upregulation have been studied in CTCs of glioma patients but
specifically, if these can be employed to diagnose BrM
still needs to be ascertained [89].
In patients’ blood samples, a subset of EpCAM-negative CTCs having expression for urokinase plasminogen activator receptor (uPAR) and integrin β1 (int β1)
were also found to be contributing to BrM [91]. The
study shows that if CTCs are isolated with high uPAR
or integrin-β1, it would probably hint us towards BrM,
and these CTCs can be harvested from either blood or
CSF. Although finding the CTCs in CSF will be more
conclusive. The CTCs from the pleural effusion of BC
patients were enriched for BrM and revealed that these
CTCs also express COX2 (PTGS2) and growth factor receptor (GFR) ligand HBEGF that help them in
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Fig. 1 Brain metastases occur when cancer cells migrate from their primary site commonly lung, breast, colon, kidney, and melanoma to the
brain. Circulating tumor cells (CTCs) or disseminated cancer cells are continuously shed from the tumor that survives in the bloodstream and can
seed secondary tumors. The CTCs can house at metastatic sites and go dormant, which can eventually come out of the dormancy triggered by
various mechanisms. (A) Brain stroma has plasmin that converts the astrocytic FasL into paracrine death signal for the metastatic cancer cells and
inhibits L1CAM, needed for vascular co-option and metastatic outgrowth. In brain metastasis, anti-plasminogen activator (PA) serpins inhibit the
plasmin (via inhibiting plasminogen activator) that guards the cells against FasL attack and activates the L1CAM that helps in vascular co-option
of the brain metastatic cells. (B) STAT3 was found to label a subpopulation of astrocytes that were reactive and required for BrM. Brain metastatic
cells had upregulated cytokines like MIF, TGF-α, and EGF that induced the STAT3 activation via phosphorylation leading to astrospheres formation
that was capable of suppressing CD8+ T-cells. Reactive astrocytes also induce MIF to activate the MIF-CD74 axis to promote the outgrowth in BrM.
(C) Cathepsin S proteolytically cleaves the junctional adhesion molecules, JAM-B in blood-brain barrier and helps in the transmigration of brain
metastatic cells. Cathepsin S is elevated in primary tumors as well as in the macrophages of the stroma in TME

the extravasation whereas, ST6GALNAC5 promotes
breaching of BBB [37]. In BC BrM, N-myc downregulated gene family (NDRG1) involved with DNA repair
has shown to be pivotal in driving cancer cells to the
brain [92, 93]. Knockout of NDRG1 halted the BrM,
which was otherwise close to 100% in cells with high
positivity for NDRG1 [94]. Thus, CTCs with high
NDRG1 could make the patient susceptible to BrM;

however, further studies are warranted to validate their
diagnostic capabilities.
Interestingly, EpCAM negative CTCs also expressed
marker genes like EGFR, ALDH, urokinase plasminogen activator receptor, mucin1, syndecan-1, and caveolin1, that could be associated with a high propensity for
BrM and exploited as a signature for BrM [36, 39]. However, the presence of EpCAM does have the potential in
demarking the distant metastasis, though the frequency
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of CTCs obtained was less in BrM than in other organ
metastases [95]. Some small cohort studies have revealed
that patients with oligometastases have a better prognosis compared to patients having multiple metastases;
however, the oligometastatic patients with high CTCs
have a poor prognosis, and thus CTCs can help to stratify
patients eligible for specific/targeted therapeutic strategies [95–97].
Consistent data has shown that T-Cell infiltration in
brain metastatic lesions and isolation of T-cells from
CSF are of the same clonotypes, indicating an interaction among them, which can be subsequently exploited
for non-invasively predicting response to immune checkpoint inhibitors (ICI) and development of prognostic biomarkers [98]. Like cytotoxic lymphocytes isolated from
CSF were characteristically similar to the tumor lesions,
allowing to monitor inflammation on treatment with ICI
[99].
Circulating tumor DNA

Cell-free or circulating tumor DNA (ctDNA) in cancer patients’ blood was first described in 1948, and later
studies indicated its level to be high, specifically in cancer patients with genomic alterations in tumor suppressor gene, oncogenes, microsatellite instability/epigenetic
alterations derived from a tumor. However, information
regarding their release mechanism and characteristics is
still limited [100–105]. Possible routes of ctDNA in blood
could be from apoptotic cells or macrophages engulfing the necrotic cells [106]. Unlike CTCs, ctDNA isolation does not require enrichment for specific rare cell
type populations and is usually preferred for genotyping
or studying drug responses [107]. ctDNA is not limited
to cancer but also to other pathologies like autoimmune
disease, cardiac dysfunction, inflammation, and even
in pregnancy, though it gets elevated in cancer with the
fragments of mutant DNA being detected in blood [100].
During metastasis, collateral tissue damage is seen in
patient serum through elevated cfDNA having specific
methylation patterns and could be used to correlate with
distant organ metastasis [108–111]. A recent study found
elevated hepatocyte-derived cfDNA and markers for
liver damage, aspartate transaminase (AST), and alanine
transaminase (ALT) were significantly correlated in liver
metastasis, which was absent in healthy controls [112].
In patients with BrM, cfDNA from neurons, oligodendrocytes, or astrocytes having distinct methylation patterns were significantly upregulated in the serum samples
as compared to other cancer patients or patients with
metastasis to extra cranial regions [112].
The level of ctDNA is not merely dictated by tumor
volume, but it also depends on the genotype of the
ctDNA; for example, in the case of NSCLC, it depends
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on mutation in EGFR or TP53 gene [113]. Suppose
ctDNAs with specific mutations can be detected in
the blood associated with malignancy. In that case, it
can aid in screening for relapse and can be tracked for
ctDNA clearance as the presence of detectable ctDNA
is associated with poor survival, and undetectable
ctDNA has higher survival [114]. A study on Korean
NSCLC populations (n = 311) showed a significant
association of EGFR mutation status with the BrM, the
status of EGFR was the same in 71% of tissue and serum
samples [40]. In some studies, clonal evolution was
tracked by genotyping the ctDNA in blood. It revealed
how KRAS mutation in a small subclone of cells evolved
from tumors predominantly having WT-KRAS, thereby
generating resistance to EGFR antibodies. Interestingly, on the withdrawal of the antibody treatment, the
ctDNA with KRAS mutation declined in the blood, further strengthening the importance of tracking clonal
evolution post clinical interventions [115, 116]. It has
been suggested that ctDNA after surgery could be a
primary prognostic marker; and also post-chemotherapy ctDNA analysis can stratify patients. The high-risk
patients prime unique opportunities to explore aggressive therapeutic approaches. Treatment of patients
considering the ctDNA level but no radiological evidence of disease after adjuvant chemotherapy could, in
theory, even eradicate the minimal residual disease and
increase the chances of cure [117]. ctDNA can guide
the understanding of the progressions in the metastatic
cascade from monoclonal or polyclonal seeding [118,
119].
In LC BrM, TGFβ1 is known to influence metastasis,
there is one mutation in TGFβ1 having a variant corresponding to rs1982073. This mutation is associated
with poor survival, and metastasis to the brain is quite
evident in NSCLC patients’ samples (n = 205) having received radiation as a part of the treatment regimen [43]. EGFR pathway is also critically involved, as
prospective studies revealed, in how a mutation in
the EGFR gene is correlated with BrM and, in some
instances, with the number of metastases [120, 121].
Detection of ctDNA in CSF and blood revealed mutations in the EGFR gene and their concurrence with
BrM. The frequency of ctDNA in CSF was higher up
to 90% cases and around 60% cases in blood samples in
the patients [44, 45]. ALK translocation and amplification have been reported in BrM with RET gene fusion;
however, their clinical implication is still in its infancy
[122, 123]. Mutations in KEAP1, NRF2, and P300 genes
are also associated with LC BrM, which could help
cells to survive in circulation [34]. Usually, the interaction between KEAP1 and NRF2 is lost on mutations in either of the genes. However, in CTCs, NRF2
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neh2 domain was found to have R34G, E79Q and E82G
mutation, that eventually led the NRF2 to translocate
to nucleus that otherwise, was located in the cytoplasm
and changed the transcriptional profile of the CTCs
[34, 124].
PIK3CA activation was quite evident as it helps in
fatty acid generation; thereby, activating mutations
in PIK3CA are the primary lookout in the ctDNA of
HER2+ positive cells [125]. This looks relevant when
we see HER2+ BC metastasizes to the brain, and the
TNBC showing BrM can have HER2+ cells in the circulation [80]. Genetic alteration in ALK, MDM2, ATM,
BRCA1, FGFR1 and KRAS were associated with BrM
and the ctDNA from peripheral blood of the patients
were persistent with the same mutations as seen in fresh
tissue samples [41]. The deletion of PTEN, a negative
regulator of the PI3K-AKT pathway, contributes to the
upregulation of the PI3K-AKT pathway and activates
NF-kB signaling [126]. CtDNA has also been exploited to
assess the clinical implications longitudinally. BrM from
LC involved the use of 100 TRACERx (TRAcking nonsmall cell lung Cancer Evolution through therapy (Rx)),
tracking the evolution of ctDNA profile with longitudinal therapy, paving the way for ctDNA driven therapeutic modalities [18]. Besides all these genes, SERPINI1
was also frequently mutated in BrM patients. This might
help metastatic cancer cells to adapt in the circulation
and eventually extravasate to form metastases [127]. Epigenetic changes are usually seen in metastatic samples,
and in some studies, they have tried to use a serum to
read the difference in the epigenetics of primary tumor
and metastatic cancer cases [128]. In one such study,
methylation pattern was studied for miR124-2, CTD2028 M8, CCDC8, and miR3193 in primary and ctDNA.
There was 100% concordance with the tissue status in
miR124-2 and CTD-2028 M8. However, CCDC8 showed
80%, and miR3193 had a 50% similar status [42]. Out of
these genes miR124-2, CCDC8 were found to be hypermethylated, whereas miR3193was hypomethylated. Lung
cancer genome-wide DNA demethylation was studied,
and methylation patterns in tissue and blood samples
were concordant. The patients’ sample reflected poor
global methylation in BrM [129].
In melanoma BrM, BRAF or NRAS mutations are
more prominent [130]. V600E/K is among the mutation
in BRAF, and NRAS has a mutation at Q61/G12/G13
associated with BrM [46, 131–135]. These mutations
were found in ctDNA from the blood of metastatic melanoma patients [136]. A subsequent mutation in STK11/
LKB1 makes it more invasive towards the brain. They are
involved with activating phosphorylation STAT3/5 and
the FAK pathway [137]. All these studies were done on
solid tumor, however, during a clinical trial, it was found
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that 84% cfDNA, BRAF status and tumor mutation status
was in agreement, and this could be a viable option as a
prognostic marker [46].
Proteins and metabolites

Cytokines and chemokines have a prominent role in
metastasis, in fact, several studies have shown how the
seed and soil concept is recapitulated in the context
of the chemokine’s functioning [138, 139]. One study
revealed how LC cells when treated with TGFβ1 protein and were injected in mice, the chances of BrM were
3-folds higher than the cells that did not get any pretreatment with TGF-β [140]. Reduction in secreted CTSS protein, as discussed earlier in circulating tumor cells, led to
diminished BrM, which can be evaluated as a biomarker
[76, 141]. With PTEN loss in brain metastatic tumor
cells, CCL2 secretion is enhanced, leading to the recruitment of the myeloid cells that drive proliferation [126].
However, not only chemokines or other small immune
factors, but many proteins, especially like EGFR, HSPG2,
FASN, FN-1 or PYGB can be detected in blood and are
also implicated in BrM [142]. JAK2/STAT3 signaling is
also shown to be involved in BrM, and IL6 could be initiating this axis, and it has been found to be upregulated in
serum samples of NSCLC patients, significantly correlating with BrM [49]. Annexin A1 was also found upregulated in the sera of the SCLC patients, and annexin A1 is
involved in trans-endothelial migration as knockdown of
it led to diminished trans-endothelial migration in-vitro
and prevented brain metastasis in mice [143]. Similarly,
S100B was elevated in the serum of NSCLC patients,
and later it was found that S100B was implicative in BrM
[50, 144]. The same results were seen in SCLC, which
also showed elevated expression of S100B in the sera of
the patients with BrM [145]. Later it was revealed that
S100B autoantibodies could also be used to identify BrM
patients [146]. In another study where HER2 and S100B
were analyzed in serum, only HER2 levels in serum were
correlated with the BrM [147].
In LC, the expression of myelin basic proteins was
upregulated in the sera of patients with BrM [51]. This
upregulation could be due to the breaching of BBB that
could have led to the build-up of myelin in the serum.
Another important study exploited the prognostic capability of drug resistance protein that later revealed the
increased expression of multidrug resistance protein
(MRP) and in LC metastasizing to the brain [148]. MRP
is thought to be involved with the prevention of the influx
and promotes efflux at the BBB, and therefore chemotherapeutic drugs are ineffective [149].
The tumor microenvironment within BrM was
enriched for VEGF-A, TIMP-1, extracellular matrix proteins (ECMs) and Lipocalin-2 molecules that are also
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implicative in immune suppression [150–155]. Soluble
VEGFR-1 was also found to be increased in the BrM
patients’ serum and CSF [52, 156, 157]. Thereby, when
tyrosine kinase inhibitor targeting endothelial VEGF
was used, it inhibited angiogenesis with a concurrent
decrease in BrM. A recent study assessed a panel of
proteins in serum and found glial fibrillary acidic protein associated with the potential of BC to metastasize to brain; however, this still needs to be assessed in
different or large cohorts of patients [53]. In a patient
study, C-reactive protein levels in the blood distinguished the brain metastatic patients from glioblastoma,
that included 29 patients; however, primary tumor origin
was unknown, but this could be a good diagnostic marker
if it stood thorough validations [48]. Similarly, neuron
specific protein neurofilament light chain (NfL) release
due to neuron degradation was found to be high in serum
samples of patients with BrM, and also high NfL patients
had poor survival [55]. Cytokine CXCL13 and CX3CL1
were high in the serum of breast cancer patients, which
could eventually led to enhanced permeability [56]. Tau
protein, majorly located in CNS, involved in microtubule
stabilization and polymerization, was evaluated for diagnosing BrM from BC, and it was revealed that Tau level
in serum could independently predict BrM [54]. Study on
BC patients (n = 113) also found to express elevated levels of Angiopoietin-like 4 (ANGPTL4), which could help
in trans endothelial passage of the BC cells via interacting
with the integrin, cadherin, and claudin-5 [158].
A recent study showed that the astrocyte-derived
laminin-211 sequestered YAP protein and held disseminated tumor cells quiescent at the astrocyte endfeet, and
from these quiescent cells even a single cell on release
could give rise to BrM [159]. Laminin-induced changes,
if can be detected in the CSF or serum, can give a glimpse
about a likely BrM as done in some neurological disorders like Alzheimer’s disease could help in understanding the diagnosis of BrM [160]. However, its use as a BrM
diagnostic factor still needs to be investigated.
Renewed interest in cancer metabolism, the reprogramming in the metabolism of the tumor tissues with
the advent of higher resolution mass spectrometry, led
to the profiling of the metabolites through the targeted
or untargeted metabolomics revealing neo-metabolites
or oncometabolites elevated in body fluids that could
be utilized for diagnostic and therapeutic implications
[161–164]. Single-cell RNA sequencing data clearly
showed that the primary BC cells were highly glycolytic, and the metastatic tumor cells exhibited more
oxidative phosphorylation (OXPHOS) (Fig. 1). This
could pave the way for further research into assessing
these metabolites in the OXPHOS and can be put into
research to look for diagnosis and therapeutics with
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prognostic assessments [165]. In fact, the first metabolite identified was 2-hydroxyglutarate (2HG) detected
in glioma patients with a mutation in IDH 1 [164].
Diagnosis based on MR spectroscopy is based on the
metabolites assessment and could noninvasively define
a few metabolites in the brain [166, 167]. CSF-derived
metabolites have consistently helped in discriminating
different brain tumor types [168]. Brain metastatic cells
going to the brain reprogram their metabolism to adapt
the brain microenvironment, and this reprogramming
lead to distinct metabolite features [168–172].
In a cohort, with 88 BC patients, out of which 33
had BrM, the serum metabolomics revealed some
significant changes in various metabolites. In amino
acids, alanine, valine, proline, glycine, serine, threonine, phenylalanine, and arginine were upregulated. In
sugar, fructose and similarly, lipid sphingosine, besides
fumarate, lactate, and pyroglutamate all were found
to be higher in the serum of the BrM patients. These
metabolites were responsible for the amino acyl tRNA
biosynthesis and nitrogen metabolism and these were
upregulated in brain metastatic patients [173]. However, more exhaustive, and multi-center data will help
reach a consensus. Another interesting study indicated
a correlation between metabolic fingerprints to BrM in
animal models [174]. Mice were injected with B16F10,
MDA-MB-231 BR, and 4 T1-GFP cells intracerebrally
or intracardially, and a predictive model was achieved
based on the urine metabolites that indicated both
sensitivity and specificity. The metabolites detected
by NMR spectroscopy in the urine showed differential
expression of allantoin, citrate, trimethylamine, trimethylamine-N-oxide, 2-oxoglutarate, creatinine, taurine, and creatine with phosphocreatine [174]. These
metabolites were time-dependent and able to diagnose
early tumor progression. However, allantoin being present in all models with BrM could not be a marker for
diagnosis as human metabolism ceased before allantoin
at uric acid. In SCLC patients, high serum lactate dehydrogenase (that converts pyruvate to lactate) was found
to be associated with BrM [175]. Though LDH has been
shown to be associated with poor survival in LC but
its relevance in respect to BrM and elevated levels in
serum make it a favorable candidate for the diagnostic
marker. In BC also, LDH levels have shown the potential to predict BrM [176].
The field of metabolomics has grown exponentially in
the past decade, with new molecules with respect to cancer metabolism, being detected and added to the repertoire of the oncometabolite. If any differentially expressed
oncometabolite can be detected and is quantifiable, it
could resolve the qui vive for a diagnostic marker for
BrM.
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Extracellular vesicles

Extra cellular vesicles (EVs), also known as microvesicles, microparticles, ectosomes, exosomes, oncosomes,
and apoptotic bodies are the lipid membranous structures of diameter 30-150 nm released by the cells in the
normal physiology of cells usually for intercellular communication, immunity or in different pathological conditions like inflammation, neurodegeneration or in cancer
[177–181]. In cancer, billions of EVs increases and selectively upregulates the contents that contain DNA, RNA,
microRNA, long noncoding RNA, circular RNA, lipids,
proteins, and various metabolites, which are pivotal not
only in cancer progression but in metastasis that could be
exploited at diagnostic and therapeutic axes [177–182].
The disseminated cancer cells need to adapt, survive in
the different microenvironments and proliferate. EVs are
critically involved at this junction, with their repertoires
modulating the changes after the interaction with the
tumor cells and EVs, which can breach the physiological
barriers [126, 178, 183, 184]. The status of these biomolecules in EVs exposed to patient body fluids like blood,
CSF, saliva, pleural effusion, and ascites, as secretory biomolecules can dictate the development of non-invasive
biomarkers for BrM [185] (Fig. 2).
EVs are critically involved in modulating the TME in
a spatio-temporal manner, influencing tumor growth
and enhancing distant metastasis [186, 187]. It has been
shown that EVs could be involved in the preparation of
premetastatic niche, in fact, EVs isolated from cancer cell
lines with different propensities to metastasize to the distinct region were found to be populous at the future metastatic sites, and specific cells interacted with the EV for
their subsequent uptake [188]. The EVs express specific
surface proteins, which could assist in origin prediction,
that further help in predicting their favored metastatic
site [189]. These EVs could even help prepare the premetastatic niche for the cancer cells that were earlier
incapable of homing [187–189]. Due to heterogeneity
in EV size, capacity, and content, isolation of EVs has
become a cause of primary concern. Various protocols
have been developed to isolate EVs from plasma that can
be implicated in diagnosis, therapeutics, and monitoring the treatment regimen [190–193]. EVs having miR193a, miR-25-3p, miR-141-3p were found to be involved
in liver metastasis, this open avenue that tumor-derived
exosomes could be assessed for their possible inherent
role in BrM [194–196]. Melanoma-derived exosomes
disrupted the integrity of the BBB and induced microglia
activation [197]. Besides diagnosis or prognosis, the treatment regimen poses several challenges, including drug
efficacy or resistance, which can be addressed following
exosomes isolation and characterization. In BC cells, low
miR-567 was associated with the trastuzumab-resistance

Page 9 of 20

[198]. Similarly, higher lncRNA-SNHG14 containing
exosomes or lncRNA-CCAL encoding exosomes made
colorectal cancer cells oxaliplatin resistance [199]. EVs
can also predict immunotherapy response, as in the case
of melanoma (usually have high propensity to metastasize to the brain), exosomes with PD-L1 expression were
resistant to the anti-PD1 therapy [200].
Proteins in EVs

Proteins are the most studied content of the EVs, which
can be studied for proteomic profiling that conclusively
segregates the tumor cells from the normal cells with
95% specificity [182, 189]. The multiple panels profiling
was so defined and robust that they could predict the
origin of the tumors. It is being postulated that the brain
microenvironment requires conditioning for the cancer cells outgrowth, and this pre-conditioning can come
from EVs elevated with proteins of interest, as shown
by the treatment of brain tissues with EVs derived from
brain metastatic cells that led to a fourfold increase in cell
colonization and increased invasiveness [58]. Integrins
interact with the extracellular matrix proteins in distant
colonization, regulating cell survival, stemness, and metastatic potential [201, 202]. During metastasis to the lung
and liver, the EVs are abundant with integrins, which
could be investigated to ascertain the organ-specific
metastasis; however, in the case of BrM, these exosomal
integrins are fewer compared to other organ metastasis. Nevertheless, some recent studies with EVs of brain
tropic cells showed upregulated integrin ITGβ3 [57, 188].
Integrin expression patterns can be inferred to ascertain
the organotropism after the EV’s isolation.
Interestingly, CEMIP, associated with normal brain
physiology as well as involved in cancer and inflammation, was found to be upregulated in EVs derived from
brain metastatic cells. Hyaluronic acid depolymerization, cellular calcium, and WNT signaling modulation
are some of the functions of CEMIP [58]. Another small
molecule secreted by the leukemic EVs is IL15, which
was internalized by the astrocytes that, alters their activation and increases the expression of VEGF-AA which
ultimately compromised the integrity of BBB, and IL15
inhibition can decrease CNS metastasis [203]. In SCLC
cells, there was a distinctive elevation in the S100A16
when cells were co-cultured with endothelial cells, and
this effect was inhibited when exosome secretion was
pharmacologically inhibited. Further, it was shown
that the S100A16 is involved with the maintenance of
the mitochondrial membrane potential, which actively
ensures SCLC cells survival in the brain milieu [204].
This was striking as the secondary site was releasing
factors that will help establish the cells of SCLC in the
brain, which otherwise might die on entering the brain
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Fig. 2 Cells and various factors are shed by the tumor into the circulation that can be harnessed for liquid biopsy. Blood, CSF, and urine are the
analytes that can be targeted. Usually, CTCs can give a glimpse of various abnormalities associated with DNA, RNA, proteins. ctDNA can be targeted
to infer mutations, translocation, deletion, or amplification. Exosomes are enriched with metabolites and proteins besides various non-coding
RNAs which can be present in cell-free form too. High throughput technologies like NGS, single-cell sequencing, proteomics, epigenetics, and
metabolomics can unfurl these target biomolecules, which can be implicative in BrM
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microenvironment. This opens the avenue when CSF can
be investigated for the exosomes loaded with S100A16,
making the brain susceptible to secondary tumor formations [204].
Fibronectin and cyclin D1 were among the highest
expressing proteins in the exosomes of cancer cell lines
expressing brain metastatic phenotype [205]. Fibronectin is involved with the adhesion, invasion, and metastasis of melanoma and BC cells [206]. Likewise, cyclin D1
overexpressed in BC and melanoma could be involved
in TME modulation for the survival of metastatic cells
in the brain microenvironment [207, 208]. In BC BrM
exosomes enriched with annexin II was found and that
helped in tPA-dependent angiogenesis [209]. The BrM
was reduced by 4-fold when the annexin II depleted
exosomes were used for priming that was regulating the
macrophage activation via p38MAPK, NF-kB and STAT3
pathways.
Non-coding RNA in EVs

MicroRNAs are relevant in cancer biology as their deregulation is being one of the hallmarks of cancer. Currently, microRNA-based therapies are conceived as a
therapeutic option [210]. MicroRNA dysregulation and
their transport in EVs or as circulating free microRNAs
open a window for diagnostics, where microRNAs can
decree for possible metastatic propensity to a particular
organ [211, 212]. PTEN was found to be downregulated
in brain metastatic BC cells relative to primary BC cells;
however, it was restored when cancer cells left the brain
microenvironment. This PTEN regulation was conceived
through microRNAs secreted by the astrocytes [126, 213,
214]. This process shows the relevance of the microRNAs
in BrM. Therefore, a differential expression of microRNAs in BrM from breast, lung, melanoma, and other primary cancer sites could help in early diagnosis (Table 1)
(Fig. 2).
XIST transcript, a long non-coding RNA, was downregulated in cancer cells that specifically metastasizes to
the brain and not bone, promoting EMT and activation of
c-MET. Loss of XIST induced the expression of miR-503
that decreases the M1-M2 polarization of the microglia
leading to stunted T-cell proliferation [215]. In another
study on primary BC and melanoma cell lines compared
to brain metastatic cells, miR-210 was upregulated, and
miR-19a and miR-29c were downregulated in brain metastatic cell lines [205]. miR-122 downregulates the pyruvate kinase, thereby suppressing glycolysis in non-tumor
cells in the pre-metastatic niche, leading to higher nutrient availability for the metastatic cells [216, 217]. In BC
patients with metastasis, a higher miR-122 expression
was usually demonstrated, which has been implicated
with increased glucose availability to the cancer cells
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for their survival in the brain parenchyma [218]. MiR550a-3-5p was also found to be enriched in EVs from
LC and were potentially overexpressed in EVs from LC
brain metastatic patients [59]. In advanced breast cancer,
serum shows elevated levels of miR-4428 and miR-4480
and this increase can even distinguish patients with brain
metastasis [219].
In NSCLC, lncMMP-2 was highly expressed in the
TGF-β mediated EVs that led the NSCLC to metastasize
to the brain via breaching the BBB permeability [220,
221]. A study using CSF isolated from 65 patients and
then microRNA identification using prediction analysis
of microarray showed that miR-335-5p and miR-34b-3p
were unique in NSCLC BrM specifically to the leptomeningeal metastasis samples [61]. In other studies, miR423, miR-330-3p, miR-145 were found to have potential
for diagnosis as they were dysregulated in LC BrM, but
this profiling was not done regarding exosomes [222–
226]. MiR-181c, miR-503, and miR-105 were some of the
miR enriched in BCBM and involved in the deregulation of tight junctions like N-cadherin, ZO-1, which ultimately weakens the BBB [62, 63, 197]. Now, this is critical
as this was quite an important revelation of the changes
in the actin dynamics, which promoted the uptake of
the cancer cells into the cranium. Among the tight junction studies, loss in claudin-5 has been implicated in
BBB permeability, and subsequent BrM from lung and
melanoma has also been reported [227, 228]. Therefore,
it can be said that the presence of microRNA targeting the tight junctions will eventually allow any cancer
cells in circulation with a high propensity to metastasize
to the brain. In addition, as reviewed by Kanchan et.al.
the miR-200 family was found to be upregulated in the
serum and CSF of BC BrM [64]. Likewise, miR-132-3p,
miR-199a-5p, miR150-5p, and miR-155-5p could also be
exploited for diagnosis as well as for patient prognosis
[229]. EVs interacting with astrocytes led to modulation
of the brain matrix microenvironment for the subsequent
metastasis, and these EVs were enriched with miR-301
[230]. In a very interesting experiment, melanoma cells
were injected intracranially into mice and tumor growth
was analyzed. It was found that as the tumor growth in
the brain progressed the small EVs containing miRNA,
in circulation was increased. These small EV were continuously enriched for human-specific miRNAs, which
included miR-224-5p, miR-130a-3p and miR-21-5p with
tumor progression [231].
Circular RNAs have been involved in tumorigenesis,
and progression has also been implicated in BrM, like
circBCBM1 (hsa_circ_0001944) identified in BC. It is
being postulated that circBCBM1 acted as a sponge for
miR-125a and miR-509 activity, resulting in heightened
BRD4 and MMP-9 through the Sonic hedgehog pathway

Rehman et al. Molecular Cancer

(2022) 21:113

[232, 233]. Circular RNA hsa_circ_0052112 also appears
to downregulate the miR-125a-5p in BC [234]. Interestingly in clinical samples of BC with BrM, circBCMB1
(hsa_circ_0001944) was upregulated in tumor tissues and
plasma samples [232]. In the same study, other circRNAs such as hsa_circ_0001481, hsa_circ_0000646, hsa_
circ_0001006 and hsa_circ_0000732 were also found to
be upregulated and hsa_circ_0001910, hsa_circ_0008285,
and hsa_circ_0000002 were downregulated in BC cell
lines going to the brain. LncRNA GS1-600G8.5 is found
in BrM EVs and is known to destroy the BBB by decreasing ZO-1, claudin-5, and N-cadherin [235]. Besides
upregulated lncRNAs, low expression of LncRNA
XR_429159.1 was a risk factor for SCLC BrM, regulating
the neuroepithelial transforming gene 1 (NET1) pathway [65]. LncRNA associated with BrM was named LncBM, enhancing the STAT3 phosphorylation through the
JAK2-Oncostatin M and IL-6 axis. This led to ICAM1
and CCL2 expression mediating vascular co-option and
macrophage recruitment [236].

Conclusion & future perspective
With all its challenges, liquid biopsy will be the best
option in future oncology care comprising diagnosis,
prognosis, and keeping track of the minimal residual
tumor and recurrence. It has the potential to significantly
reduce cancer-related morbidity and mortality. On the
other front, BrM, which has been lately the major problem associated with disease progression mainly in the
case of BC, LC, melanoma or clear cell renal carcinoma,
is devoid of any molecular biomarkers, which are currently in clinical practice. Therefore, understanding the
molecular features in cancer cells- especially the disseminated ones that prime these cells to specifically metastasize to the brain, will help design better diagnostic
strategies. This can be done by studying the CTCs, cellfree nucleotides ctDNA or non-coding RNAs in the form
of microRNAs, circular RNAs, or long non-coding RNAs
(Table 1). Secretory proteins and metabolites have also
shown their potential; however, there is a definite gap in
our understanding about alien cells homing the brain.
Clinical trials are underway, and among them, one is
studying the serum glutamate, aspartate, lactate, glutamate pyruvate transaminase, glutamic oxaloacetic
transaminase, and lactate dehydrogenase levels in the
BrM patients of LC, BC, and melanoma treated with
stereotactic radiosurgery and patients with the same
primary controlled tumors with neither brain nor
extracranial metastases (ClinicalTrials.gov Identifier:
NCT04785521) (Table 2). Another clinical trial is now
recruiting patients of BC (TNBC/HER2+), NSCLC,
SCLC, melanoma, and other solid tumors who have
been at high risk or close to a possible diagnosis of CNS
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metastases for the analysis of ctDNA from plasma and
CSF samples (BrainStorm Program, ClinicalTrials.gov
Identifier: NCT04109131) (Table 2). More discoveries in
this direction would enrich our portal that can be used to
screen for potential BrM.
Overexpression of neuroserpins and L1CAM could
instigate BrM, which can be further integrated with
GRIN2B and CTSS; as such, their expression makes cells
competent enough to withstand the various attacks from
the reactive brain stroma. CTCs isolated from blood and
CSF can be evaluated if they harbor such anti-PA serpins,
CTSS, and others to make metastatic cells competent in
seeding metastatic lesions in the brain. The presence of
such CTCs in blood will intimately augur a competent
future brain infiltration. However, to exploit these features as an option for liquid biopsy, we need studies with
large cohorts of patients with cancer prone to BrM.
DNA mutations can confer genes with the gain and
loss of functions mutation. Some tumor suppressor genes
become lethal on mutating and have been associated with
highly aggressive cancers [237, 238]. BRCA2, NOTCH,
RB2, KEAP1, NRF2 were among the topmost mutated
genes in metastatic BC cases. These mutations are found
in the circulating tumor DNA and, besides diagnosis and
therapeutics, it could also help in tracking the efficacy of
therapy. These mutated circulating tumor DNA can also
be found enclosed in EVs. Besides CTCs, EVs can also be
a source of proteins, metabolites, cell-free RNA, or DNA,
and non-coding RNAs (Table 1, Fig. 2). The presence of
proteins and metabolites can also be detected in serum;
some of the proteins like carcinoembryonic antigen and
carbohydrate antigen 19-9 are FDA approved to diagnose
and monitor treatment effects. EVs with artificial intelligence hinted at detecting early-stage 1 and 2 pancreatic
cancers. Liquid biopsies based on EVs are getting popular
and could be a revolution in liquid biopsy-based cancer
diagnostics [239].
Taking a cue from the vast literature on the molecules
implicated in BrM, it could be possible to use these
screenings for cancer progression. CTCs can be evaluated for the upregulated genes expression with copy
number variations and the other biomolecules. EVs will
encompass all the cell-free RNA, ctDNA, proteins, and
metabolites. ctDNAs are the best analyte, giving instant
access to mutations in the DNA. Thereby, this has led to
the idea that if clinical trials on patients at a high risk of
developing BrM are subjected to the screening of these
potential molecular profiles, it can help stratify the
patients into high or low-risk BrM groups. However, this
comes across to look for the efficacy of the molecules in
the early diagnosis. Except for relying on radiodiagnosis
or the development of neurological symptoms, no biomarker is currently available for diagnosing BrM.
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Table 2 Clinical trial on brain metastasis based on liquid biopsies
Clinical trial identifier

Liquid biopsy

NCT04785521

NCT03550391

Cancer type

Status

Outcomes/predicted outcomes

Blood samples (serum) BrM from melanoma, lung, and breast
cancer treated with stereotactic radiosurgery (SRS)

Recruiting

a) Serum GOT1, GPT, LDH, glutamate,
aspartate, and lactate determination and
comparison in:
-newly diagnosed BrM patients before
SRS treatment.
-melanoma, breast, and lung cancer
patients without BrM.
-newly diagnosed BrM and non-BrM
patients.
-patients carrying benign intracranial
lesions (before and after SRS treatment).
b) Studying correlation of serum markers
with MRI changes following SRS treatment.

Plasma and serum

Patients with BrM (all cancer types)

Recruiting

-Whether detectable somatic mutations
from liquid biopsy could be able to predict overall survival of patients with BrM
and development of new BrM.
-Analysis of serum biomarkers such as
C-reactive proteins and brain-derived
neurotrophic factors to elucidate
genomic changes or molecular mechanism of neurocognitive decline associated with BrM.
-To compare overall survival in BrM
patients who receive SRS treatment
to patients who receive hippocampalavoidant (HA-WBRT) radiotherapy.

NCT04109131 (BrainStorm) Blood sample (for
plasma & serum) CSF

TNBC/HER2+ BC, NSCLC, SCLC, and
melanoma

Recruiting

-Epidemiology of CNS metastases and
identification of risk factors for CNS
metastases (including time to first CNS
event and time to second or subsequent
CNS events after first treatment).
-Understand heterogeneity between the
primary tumor and the CNS metastasis.
-Identification of promising therapeutic
targets for novel compounds.
-Building clinico-pathological database
for patients with newly diagnosed nonCNS metastatic solid tumors with high
risk of developing CNS metastasis.
-ctDNA analysis from CSF samples.

NCT03257735

Blood and CSF

NSCLC

Recruiting

Gene mutation status in CSF, blood, and
tissues, and comparison of mutations
after first session and during tumor
progression to explore the role of liquid
biopsy in the diagnosis and therapeutic
advancement of NSCLC with BrM.

NCT02058953

Blood and CSF

Melanoma

Completed To understand if melanoma CNS metastases are similar to primary melanoma,
and development of biomarkers for
the prediction of CNS metastases from
primary melanoma.

Liquid biopsies also have limitations that get even
more aggravated when BrM has to be investigated due
to provocative anatomical and physiological discrepancies. Primarily the seed of fatal metastases, CTCs are
rare when the tumors are established but can be quite
intuitive in the sense that they have cancer-associated
abnormalities. When tumors are metastasizing and

losing cells heavily in the circulation, then short halflife of DNA or circulatory cells, is another factor for
delimiting the potential of liquid biopsies. However,
isolating CTCs from the blood or other body fluids is
challenging, implying the use of proliferation markers like Ki67, uPAR, or supplementing with antibodymediated capture; again, all these strategies come with

Rehman et al. Molecular Cancer

(2022) 21:113

their limitations, specifically when non-epithelial cells
are of interest [240]. In patients with BrM, it is even
more challenging to isolate CTCs as they are less in
numbers than extracranial metastasis [95]. In addition, liquid biopsies comparing CTCs, ctDNA, protein or metabolites either free or enclosed in EVs have
potential when they can be clubbed with surgeries as
post-surgical circulating DNA remnants pose a relapse
threat as compared with patients with no circulating
DNA features. However, the lack of sensitive technological advancement extrudes the confidence for taking
the final call on the future perspective of the disease.
Thus, it can only be used in conjunction with other factors assessment. The factors or cells secreted by the
tumor and factors secreted by the secondary metastatic
site for the successful homing. It is unknown if these
factors can breach the BBB and can be spectacled in the
circulation, so CSF examination is the best bet. Though
drawing CSF is considered safe, but for longitudnal
assesment doing lumbar punctures at regular intervals
would be quite painful, and the patients usually have
headaches after the procedure. In some extreme conditions, nerve damage or infections can make it worse.
Although significant advances in the understanding of BrM have been made, no absolute biomarker is
available that is currently being used in clinical settings,
and radiodiagnosis or PET-CT imaging is only good
when the tumor has progressed to a particular size that
can be imaged. Thus, in the future, it can be a possibility that radiodiagnosis and liquid biopsies can be
combined to diagnose BrM at an earlier stage when the
tumor burden is low. Also, it will help in separating the
responders from non-responders. With technological
advancement, more interest is currently being generated in liquid biopsies for BrM diagnosis and prognosis, and it could also prove to be effective in preventive
oncology.
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